KBC Group
NTLA icon

KBC Group’s Intellia Therapeutics NTLA Stock Holding History

KBC Group’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$50K Sell
3,928
-2,165
-36% -$27.6K ﹤0.01% 1652
2025
Q4 		$55K Hold
6,093
– – ﹤0.01% 1608
2025
Q3 		$105K Hold
6,093
– – ﹤0.01% 1226
2025
Q2 		$57K Hold
6,093
– – ﹤0.01% 1546
2025
Q1 		$43K Hold
6,093
– – ﹤0.01% 1818
2024
Q4 		$71K Buy
6,093
+2,340
+62% +$36.5K ﹤0.01% 1727
2024
Q3 		$77K Buy
3,753
+1,020
+37% +$23.5K ﹤0.01% 1459
2024
Q2 		$61K Buy
2,733
+940
+52% +$22.4K ﹤0.01% 1499
2024
Q1 		$49K Hold
1,793
– – ﹤0.01% 1572
2023
Q4 		$55K Hold
1,793
– – ﹤0.01% 1461
2023
Q3 		$57K Buy
+1,793
New +$69.6K ﹤0.01% 1337
2020
Q4 		– Sell
-2,040
Closed -$40K – 1278
2020
Q3 		$40K Hold
2,040
– – ﹤0.01% 1215
2020
Q2 		$42K Buy
2,040
+1,020
+100% +$17.3K ﹤0.01% 1249
2020
Q1 		$12K Hold
1,020
– – ﹤0.01% 1266
2019
Q4 		$15K Sell
1,020
-2,940
-74% -$40.9K ﹤0.01% 1469
2019
Q3 		$53K Buy
3,960
+3,440
+662% +$54.8K ﹤0.01% 1384
2019
Q2 		$9K Hold
520
– – ﹤0.01% 1438
2019
Q1 		$9K Buy
520
+260
+100% +$3.88K ﹤0.01% 1397
2018
Q4 		$4K Sell
260
-265
-50% -$4.93K ﹤0.01% 1305
2018
Q3 		$14K Hold
525
– – ﹤0.01% 1375
2018
Q2 		$14K Hold
525
– – ﹤0.01% 1274
2018
Q1 		$11K Hold
525
– – ﹤0.01% 1262
2017
Q4 		$10K Buy
+525
New +$12.1K ﹤0.01% 1247

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

KBC Group's NTLA Position: Q1 2026 in Review

KBC Group reduced its Intellia Therapeutics (NTLA) stake by 36% in Q1 2026, selling an estimated $27.6K and leaving 3,928 shares worth $50K. The position accounts for ﹤0.01% of the portfolio, ranked #1652.

KBC Group first reported a position in NTLA in Q4 2017 and has held it in 23 quarters since. The position peaked at $105K in Q3 2025. 303 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • KBC Group held 3,928 shares of Intellia Therapeutics worth $50K as of Q1 2026.
  • KBC Group sold 2,165 Intellia Therapeutics shares in Q1 2026, an estimated $27.6K.
  • Intellia Therapeutics made up ﹤0.01% of KBC Group's portfolio in Q1 2026, its #1652 holding.
  • KBC Group first reported a position in Intellia Therapeutics in Q4 2017 and has held it in 23 quarters since.
  • KBC Group's Intellia Therapeutics position peaked at $105K in Q3 2025.
  • 303 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on KBC Group's 13F filing for Q1 2026, filed 7 May 2026.